诚意药业: 浙江诚意药业股份有限公司关于帕拉米韦注射液获得药品注册证书的公告

Overview - Zhejiang Chengyi Pharmaceutical Co., Ltd. has received the drug registration certificate for Palivizumab injection from the National Medical Products Administration (NMPA) [1] - The approval indicates that the product meets the requirements for drug registration and is subject to pre-marketing quality management compliance inspection [1] Drug Development and Related Information - Palivizumab injection is indicated for the treatment of influenza A or B [1] - The registration application was formally accepted on March 4, 2024, with a total R&D investment of 6.6968 million yuan as of the announcement date [1] Market Situation - As of the announcement date, there are 35 manufacturers of Palivizumab injection, including Chengyi Pharmaceutical and other companies such as Zhongrun Pharmaceutical and Yangtze River Pharmaceutical Group [1] - Palivizumab injection was selected in the national centralized procurement for the tenth batch in December 2024, with a total agreed procurement volume of 249,600 units for the 15ml:0.15g specification and 5,350 units for the 60ml:0.3g specification [2] - The estimated market sales for Palivizumab injection in public medical institutions for 2024 is approximately 9.5 million yuan [2]